Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
62.818,00
-0,11%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Orgenesis Inc (ORGS) Orgenesis Inc (ORGS) Notizie

Orgenesis Inc

ORGS
0,527
-0,016 (-2,95%)
03 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
15/4/202423:07GLOBEOrgenesis Provides Year End Business Update
10/4/202418:00GLOBEGermfree and Orgenesis Announce Asset Purchase and Strategic..
18/3/202413:30GLOBEVered Caplan, CEO of Orgenesis, to Present at the..
13/3/202413:30GLOBEOrgenesis Consortium Awarded €1.5M EUR Grant from the..
04/3/202414:30GLOBEOrgenesis Inc. Announces $2.3 Million Private Placement
29/2/202414:30GLOBEOrgenesis Consortium Awarded €2.0M EUR Grant from Walloon..
31/1/202415:20EDGAR2Form 8-K - Current report
31/1/202415:15GLOBEOrgenesis Acquires Control of Octomera with the Goal of..
24/1/202422:05EDGAR2Form 8-K - Current report
22/1/202422:01EDGAR2Form 8-K - Current report
08/1/202423:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202423:36EDGAR2Form 3 - Initial statement of beneficial ownership of..
05/1/202412:02EDGAR2Form 8-K - Current report
14/11/202314:30GLOBEOrgenesis Ranked No. 171st Fastest-Growing Company in North..
13/11/202322:15GLOBEOrgenesis Provides Business Update for the Third Quarter of..
09/11/202313:41EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
08/11/202315:24EDGAR2Form 8-K - Current report
08/11/202315:00GLOBEOrgenesis Inc. Announces Pricing of $1.1 Million Registered..
02/11/202313:00GLOBEOrgenesis Announces Expanded Partnership Between Octomera..
31/10/202302:30GLOBEOrgenesis Announces Withdrawal of Proposed Public Offering
30/10/202321:07GLOBEOrgenesis Announces Proposed Underwritten Public Offering
21/9/202314:00GLOBECGT Global and Octomera Enter Agreement to Expand Cell &..
06/9/202313:00GLOBECell and Gene Therapy Industry Pioneer & GMP Expert, Gerhard..
05/9/202322:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/8/202313:00GLOBEOrgenesis Provides Business Update for Second Quarter of..
10/8/202323:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202314:30GLOBEOrgenesis Schedules Second Quarter 2023 Business Update..
13/7/202314:30GLOBEOrgenesis Appoints Finance Veteran Elliot Maltz as its Chief..
12/7/202322:05EDGAR2Form 8-K - Current report
11/7/202313:00GLOBEOrgenesis Announces Name Change of Morgenesis Business Unit..
07/6/202313:00GLOBEOrgenesis and University of California, Davis Sign..
30/5/202315:30GLOBEClaudia Zylberberg Appointed as Independent Board Member of..
22/5/202313:30GLOBEOrgenesis Academy Graduates First Class of Cell and Gene..
19/5/202314:30GLOBEOrgenesis to Participate in Benchmark’s 3rd Annual..
18/5/202313:30GLOBEOrgenesis Announces Collaboration Agreement with SCTbio to..
10/5/202322:30GLOBEOrgenesis Provides Business Update for the First Quarter of..
10/5/202316:00GLOBEOrgenesis Secures an Additional $5 Million Investment from..
Apertura: 0,547 Min: 0,505 Max: 0,5796
Chiusura: 0,543

La tua Cronologia

NASDAQ
ORGS
Orgenesis
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network